Large-scale study shows oral hydroxychloroquine and povidone-iodine throat spray can reduce spread of Covid-19 in high transmission settings
2021-04-28 · Mundipharma Research Limited · original mundipharma.com ↗
Apr 28 2021 For medical and trade media only Please refer to the official media release from the National University Health System in Singapore. IMPORTANT INFORMATION: Mundipharma’s brand of povidone-iodine throat spray, (Betadine® Throat Spray), is only indicated for use by adults and children aged 6 years and older, up to 3 sprays per day for a maximum of seven (7) days or as directed by a healthcare professional . Dosage instructions may vary by country due to local regulatory approvals. Betadine® Throat Spray is not currently authorised for the prevention or treatment of COVID-19. It is advisable to speak to a doctor if you have a thyroid condition, allergies to povidone-iodine or any ingredients in the product, if you are pregnant or breast feeding, or for usage in children.
The release as fetched from its publisher. mundipharma.com ↗